Rituximab (MabThera)

Approval in the US

The US product name for MabThera is Rituxan.

All content found on this website, including text, images, audio, or other formats were created for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Understanding Cancer Immunotherapy Research